Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Case Reports
. 2025 May 8:61:129-132.
doi: 10.1016/j.jdcr.2025.03.037. eCollection 2025 Jul.

Dermatitis herpetiformis successfully treated with dupilumab

Sara Al-Khawaga  1   2   3   4   5 , Ashraf I Ahmed  6 , Fatima Al-Khawaja  1 , Dana Jassim AlShibani  1 , Fatima E Al-Kubaisi  4 , Samir Al Hyassat  7 , Abdelkareem Alhyari  7 , Joerg Buddenkotte  1   2   3 , Martin Steinhoff  1   2   3   4   5   6   8
Affiliations
Case Reports

Dermatitis herpetiformis successfully treated with dupilumab

Sara Al-Khawaga et al. JAAD Case Rep. .
No abstract available

Keywords: celiac disease; dermatitis herpetiformis; dupilumab; glycogen storage disease.

PubMed Disclaimer

Conflict of interest statement

Dr Steinhoff is a consultant for Pfizer, Janssen, Eli-Lilly, Novartis, Abbvie, UCB, Celgene, Galderma, Leo, MenloTx, Sanofi, Regeneron. They received grants by Pfizer, Novartis, Leo, Galderma; and are a speaker for Pfizer, Janssen, Eli-Lilly, Novartis, Abbvie, UCB, Celgene, Galderma, Leo, MenloTx, Sanofi, Regeneron. Buddenkotte and Al-Khawaga were investigators in a Novartis-sponsored clinical study. Drs Ahmed, Al-Khawaja, AlShibani, Al-Kubaisi, Al Hyassat, and Alhyari have no conflicts of interest to declare.

Figures

Fig 1
Fig 1
Cutaneous presentation of symmetrically erupted vesicles and papules located on (A) arm and (C) above the he left medial malleolus, respectively and clinical improvement by dupilumab treatment (B, D). With kind permission from the patient.
Fig 2
Fig 2
Dermato-histopathological examination of the papule revealed (A) upper dermal inflammation (H&E, 2× magnification), (B) mild spongiosis with prominent basal vesicular degeneration accompanied with prominent lymphocytic infiltration and focal pigment incontinence inflammation (H&E, 20× magnification), and (C) granular immunoglobulin A (IgA) immunofluorescence staining along the dermoepidermal junction and dermal papillae.
See this image and copyright information in PMC

References

    1. Reunala T., Hervonen K., Salmi T. Dermatitis herpetiformis: an update on diagnosis and management. Am J Clin Dermatol. 2021;22(3):329–338. - PMC - PubMed
    1. Antiga E., Maglie R., Quintarelli L., et al. Dermatitis herpetiformis: novel perspectives. Front Immunol. 2019;10:1290. - PMC - PubMed
    1. Kishnani P.S., Austin S.L., Abdenur J.E., et al. Diagnosis and management of glycogen storage disease type I: a practice guideline of the American College of Medical Genetics and Genomics. Genet Med. 2014;16(11):e1. - PubMed
    1. Kahn J.S., Moody K., Rosmarin D. Significant improvement of dermatitis herpetiformis with tofacitinib. Dermatol Online J. 2021;27(7):6. - PubMed
    1. Albers L.N., Zone J.J., Stoff B.K., Feldman R.J. Rituximab treatment for recalcitrant dermatitis herpetiformis. JAMA Dermatol. 2017;153(3):315–318. - PubMed

Publication types

LinkOut - more resources